Urology Practice Valuation Benchmarks: 2026
Urology practices enter 2026 with valuation dynamics defined by earnings durability, procedural demand, and scale. While overall healthcare services M&A activity remains below the post-pandemic peak, pricing for high-quality specialty physician platforms has remained stable. Buyers continue to differentiate sharply between scaled urology groups with institutional infrastructure and smaller practices where cash flow remains closely tied to individual physicians.
Valuation outcomes increasingly reflect operational discipline rather than topline growth. Practices that demonstrate consistent utilization, integrated ancillaries, and stable provider retention attract broader buyer interest and achieve stronger pricing outcomes, positioning urology alongside other core procedural specialties.
Strategic Interest
Urology has enjoyed increasing interest from strategic buyers, including distributors like Cardinal Health (which acquired Solaris Health, a urology platform, in 2025). This has helped expand private equity’s interest in the space and charts a potential path to recapitalization.
FOCUS has observed similar trends in adjacent specialties, including retina, oncology, and gastroenterology. Some strategic buyers have even moved to consolidate these high-interest specialties (e.g., Urology America’s combination with GI Alliance and United Urology Group’s sale to OneOncology).
Urology Valuation Ranges (Platform vs Add-On)
Urology is typically evaluated alongside other core procedural specialties such as ophthalmology, gastroenterology, and cardiology. As a result, valuation expectations generally align with broader specialty physician benchmarks, with outcomes driven by factors like scale and transaction structure.
EBITDA multiples remain the primary pricing mechanism in urology transactions. Revenue multiples are included for directional context only and vary widely based on operating efficiency, site-level economics, and clinical mix.
| Transaction Type | EV / EBITDA Range | Commentary |
|---|---|---|
| Platform acquisition | ~10–14× | Supported by scale, governance and ancillary density |
| Add-on acquisition | ~5–9× | Driven by integration readiness and physician retention |
| Revenue multiple (reference) | ~0.9–1.5× | Highly sensitive to margin and payer mix |
Source: Healthcare Services Valuation Benchmarks (2025); PitchBook Healthcare Services Research, internal knowledge and experience in healthcare services.
*Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
Valuation by EBITDA Scale
Scale is one of the most decisive valuation drivers in urology. As practices grow, the buyer universe expands and pricing dynamics shift meaningfully.
According to PitchBook, private equity buyers consistently target physician platforms with sufficient EBITDA to support centralized management, reporting discipline, and multi-site growth. Practices below the institutional scale often transact through narrower processes, limiting competitive tension.
Market data and banker experience shows that medical practices crossing the $3M EBITDA threshold often experience a step-change in valuation rather than incremental improvement. This reflects buyer preference for assets that can absorb professionalized overhead and support add-on execution.
| Trailing EBITDA | Typical Valuation Profile |
|---|---|
| <$1.5M | Limited institutional demand; pricing constrained |
| $1.5–3M | Entry-level sponsor interest with improving multiples |
| $3–5M | Core acquisition range with competitive buyer interest |
| $5M+ | Platform-level outcomes possible with governance and density |
Source: PitchBook Healthcare Services Research
*Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
Key Drivers of Urology Valuation Premiums
Buyers focus on the sustainability and scalability of earnings rather than short-term revenue growth. Several operational factors consistently influence pricing outcomes in urology transactions.
According to VMG Health’s 2025 M&A Report, specialty physician practices that control downstream revenue and demonstrate procedural depth are more likely to achieve premium outcomes compared with peers reliant solely on professional fees.
Practices with operationally integrated ancillaries tend to outperform peers in valuation outcomes. Control over surgical access and consistent utilization are particularly important in urology underwriting.
ASC ownership: Improves margin visibility and downstream control
Ancillary services: Enhances EBITDA quality and diversification
Subspecialty mix: Supports procedural depth and differentiation
Physician retention: Reduces transition risk and earnings volatility
| Value Driver | Impact on Valuation |
|---|---|
| ASC ownership | Improves margin visibility and downstream control |
| Ancillary services | Enhances EBITDA quality and diversification |
| Subspecialty mix | Supports procedural depth and differentiation |
| Physician retention | Reduces transition risk and earnings volatility |
Source: VMG Health 2025 M&A Report
Buyer Landscape for Urology Practices
Urology practices attract a diverse buyer universe, though valuation behavior differs materially by acquirer type.
According to PitchBook’s healthcare services research, financial sponsors remain the most consistent acquirers of mid-market specialty physician platforms. Strategic buyers and health systems participate selectively, often driven by regional coverage or referral alignment rather than platform expansion.
Even when multiple buyer types are present, sponsor-backed platforms frequently set valuation expectations due to their willingness to underwrite growth, integration, and professionalized operations.
| Buyer Type | Typical Valuation Approach |
|---|---|
| Private equity-backed platforms | Lead pricing for scaled assets |
| Strategic physician groups | Selective, regionally focused |
| Health systems | Opportunistic, strategy-driven pricing |
Source: PitchBook Healthcare Services Research
Market Context Entering 2026
Several macro trends support urology’s relative stability entering 2026. According to the PitchBook 2026 Healthcare Outlook, healthcare services activity is positioned to rebound as extended sponsor hold periods unwind and valuation expectations converge. Specialty practices with essential care characteristics are expected to benefit disproportionately from this release of pent-up transaction volume.
Demographic tailwinds also support urology utilization. An aging population and rising prevalence of urologic conditions contribute to predictable procedural demand. Compared with elective specialties, urology exhibits lower exposure to discretionary spending cycles, improving earnings visibility for buyers.
Common Misconceptions About Urology Valuation
Despite favorable fundamentals, valuation outcomes often fall short of expectations due to structural issues rather than market conditions.
According to Scope Research’s Healthcare M&A Valuation Review, dispersion between top- and bottom-quartile outcomes has widened across physician services, driven primarily by differences in scale, governance, and process quality.
Common pitfalls include:
Revenue growth without margin durability, which does not translate into higher pricing.
A strong, profitable single location is not the same as a scalable platform. Without infrastructure to support multiple sites, centralized management, and future expansion, buyers typically value it as an add-on rather than a platform, which usually means lower multiples. This is especially true when productivity is concentrated in a small number of providers and ancillaries are limited.
Unstructured sale processes, which limit buyer competition and compress outcomes.
Learn More
FOCUS Investment Banking specializes in maximizing transaction value for healthcare practice owners through our proven quarterback approach to M&A advisory.
If you’d like to learn more about our healthcare investment banking services, you can reach out here.
All valuation ranges are presented for educational purposes only and are not a guarantee of any outcome. Transactions are typically priced on a multiple of EBITDA. Revenue multiples can vary widely based on margin, operational efficiency, and clinical mix.
Sources
